Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers

QR Code

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers

Enregistré dans:

Détails bibliographiques
Auteur principal:	Yingyan Yu
Format:	article
Langue:	EN
Publié:	China Anti-Cancer Association 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/676103e2d9b549fea31e5a6893d8b918
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Acute kidney injury in patients treated with immune checkpoint inhibitors
par: Enriqueta Felip, et autres
Publié: (2021)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
par: Andrew Haydon, et autres
Publié: (2021)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
par: Ben‐Yuan Jiang, et autres
Publié: (2021)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
par: Anne R Bass, et autres
Publié: (2021)

68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
par: Joe-Elie Salem, et autres
Publié: (2021)

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
par: Edward J Spangenthal, et autres
Publié: (2021)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
par: Ye-Jee Kim, et autres
Publié: (2021)

Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
par: Feicheng Wang, et autres
Publié: (2021)

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
par: Tomas G Neilan, et autres
Publié: (2021)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Publié: (2021)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
par: Michael Dougan, et autres
Publié: (2021)

Correction: TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
Publié: (2021)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
par: Paolo Antonio Ascierto, et autres
Publié: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
par: Ke Cheng, et autres
Publié: (2021)

Correction: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Publié: (2021)

Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
Publié: (2021)

Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model
par: Chiao-Fang Teng, et autres
Publié: (2020)

Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
par: Alice Tzeng, et autres
Publié: (2021)

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
par: Kun-Hsing Yu, et autres
Publié: (2021)

Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
par: Chiao-Fang Teng, et autres
Publié: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
par: Frank Riemer, et autres
Publié: (2021)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
par: Dirk Schadendorf, et autres
Publié: (2021)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
par: James Harber, et autres
Publié: (2021)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
par: Marco Donia, et autres
Publié: (2021)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Publié: (2021)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
par: Shunichi Taki, et autres
Publié: (2021)

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
par: Dobrin Draganov, et autres
Publié: (2021)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
par: Guru Sonpavde, et autres
Publié: (2021)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
par: Chisato Ohe, et autres
Publié: (2021)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
par: Shahram Salek-Ardakani, et autres
Publié: (2021)

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
par: Theresa L Walunas, et autres
Publié: (2021)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
par: Nicola Personeni, et autres
Publié: (2021)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
par: Giustini N, et autres
Publié: (2021)

In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
par: In-San Kim, et autres
Publié: (2021)

Correction: In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
Publié: (2021)

Progress of Immune Checkpoint Inhibitors  in the Treatment of Advanced Pulmonary Neuroendocrine Tumors
par: Haoqing CHEN, et autres
Publié: (2021)

Are another 5 years of adjuvant aromatase inhibitor therapy needed?
par: Mo QG, et autres
Publié: (2016)

Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy
par: Yael Artzy-Randrup, et autres
Publié: (2021)

Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy
par: Alberto Carmona-Bayonas, et autres
Publié: (2021)

FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity
par: Simon Timbrell, et autres
Publié: (2021)